-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Multiple myeloma patients are high- risk patients with severe COVID-19 .
COVID-19
Compared with the control group, the anti-spinous IgG levels of multiple myeloma patients decreased, but the proportion of patients who achieved a humoral response was high (89% vs 97%, the control group)
Overall, these results support that the response of MM patients to the two doses of anti-SARS CoV 2 BNT162b2 vaccine is lower than that of HC
Immunity
Original source:
Bitoun, S.
Bitoun, S.
, Henry, J.
, Vauloup-Fellous, C.
et al.
Response to COVID-19 mRNA vaccination in multiple myeloma is conserved but impaired compared to controls.
J Hematol Oncol 14,166 (2021).
https:/ /doi.
org/10.
1186/s13045-021-01183-2 Leave a message here